Last reviewed · How we verify
NCT04662294
CD 70 CAR T for Patients With CD70 Positive Malignant Hematologic Diseases
Recruiting now
EARLY_PHASE1
Last updated 4 November 2021
What this trial tests
EARLY_PHASE1 trial testing CD70 CAR T-cells in Acute Myeloid Leukemia in 108 participants. Currently enrolling.
Timeline
18 November 2021
Primary endpoint
15 January 2024
15 January 2024
15 January 2027
Quick facts
| Lead sponsor | Zhejiang University |
|---|---|
| Phase | EARLY_PHASE1 |
| Status | Recruiting now |
| Study type | INTERVENTIONAL |
| Allocation | non randomized |
| Design | single group |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 108 |
| Start date | 18 November 2021 |
| Primary completion | 15 January 2024 |
| Estimated completion | 15 January 2027 |
| Sites | 1 location across China |
Drugs / interventions tested
- CD70 CAR T-cells — full drug profile →
Conditions studied
- Acute Myeloid Leukemia — all drugs for Acute Myeloid Leukemia →
- Non-hodgkin's Lymphoma — all drugs for Non-hodgkin's Lymphoma →
- Multiple Myeloma — all drugs for Multiple Myeloma →
Sponsor
Zhejiang University
Who can join
Eligibility, any sex, with Acute Myeloid Leukemia or Non-hodgkin's Lymphoma. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
A Study of CD 70 CAR T for patients with CD70 positive malignant hematologic diseases
Publications & conference data
8 peer-reviewed publications reference this trial (live from Europe PMC):
-
The CD70-CD27 axis in oncology: the new kids on the block.
Flieswasser T, Van den Eynde A, Van Audenaerde J, De Waele J, et al · · 2022 · cited 146× · PMID 34991665 · DOI 10.1186/s13046-021-02215-y -
CAR-T cell therapy for cancer: current challenges and future directions.
Zugasti I, Espinosa-Aroca L, Fidyt K, Mulens-Arias V, et al · · 2025 · cited 81× · PMID 40610404 · DOI 10.1038/s41392-025-02269-w -
Patient selection for CAR T or BiTE therapy in multiple myeloma: Which treatment for each patient?
Kegyes D, Constantinescu C, Vrancken L, Rasche L, et al · · 2022 · cited 53× · PMID 35672793 · DOI 10.1186/s13045-022-01296-2 -
Recent Advances in Immune-Based Therapies for Acute Myeloid Leukemia.
Restelli C, Ruella M, Paruzzo L, Tarella C, et al · · 2024 · cited 36× · PMID 38904305 · DOI 10.1158/2643-3230.bcd-23-0202 -
Structural surfaceomics reveals an AML-specific conformation of integrin β<sub>2</sub> as a CAR T cellular therapy target.
Mandal K, Wicaksono G, Yu C, Adams JJ, et al · · 2023 · cited 33× · PMID 37904046 · DOI 10.1038/s43018-023-00652-6 -
Biomarkers as targets for CAR-T/NK cell therapy in AML.
Shao R, Li Z, Xin H, Jiang S, et al · · 2023 · cited 32× · PMID 37330575 · DOI 10.1186/s40364-023-00501-9 -
Preclinical development and evaluation of nanobody-based CD70-specific CAR T cells for the treatment of acute myeloid leukemia.
Cheng J, Ge T, Zhu X, Wang J, et al · · 2023 · cited 32× · PMID 36932256 · DOI 10.1007/s00262-023-03422-6 -
Challenges and Advances in Chimeric Antigen Receptor Therapy for Acute Myeloid Leukemia.
Marvin-Peek J, Savani BN, Olalekan OO, Dholaria B. · · 2022 · cited 30× · PMID 35158765 · DOI 10.3390/cancers14030497
Verify or expand the search:
- PubMed search for NCT04662294
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Acute Myeloid Leukemia
Currently open trials in the same condition.
- NCT07020533 — A Vaccine (CMV-MVA Triplex Vaccine) for the Enhancement of CMV-Specific Immunity and the Prevention of CMV Viremia in Pa · Phase 1 · recruiting
- NCT06782542 — Olutasidenib, Venetoclax, and Azacitidine in IDH1 Mutated Newly Diagnosed Acute Myeloid Leukemia Patients Eligible for I · Phase 2 · recruiting
- NCT07177079 — High-dose Ascorbate (HDA) in Combination With Standard of Care Azacitidine and Venetoclax in Acute Myeloid Leukemia (AML · Phase 1 · recruiting
- NCT07384715 — First-in-human (FIH) Trial of GEN3018 in Relapsed or Refractory (R/R) Acute Myeloid Leukemia (AML) or Higher-risk Myelod · Phase 1 · recruiting
- NCT07107126 — Safety and Proof-of-Concept Study of RPT1G in Adults With Acute Myeloid Leukemia and High-Risk Myelodysplastic Syndromes · Phase 1 · recruiting
Other Zhejiang University trials
Trials by the same sponsor.
- NCT07487402 — Safety and Efficacy of Metabolically Armed GPC3 CAR-T Cells Injection (Meta10-GPC3) in Patients With Unresectable Recurr · EARLY_PHASE1 · not yet recruiting
- NCT07480044 — A Phase II Clinical Two-Stage Study of Transcranial Magnetic Stimulation in Preventing Postoperative Delirium in Elderly · NA · not yet recruiting
- NCT07467005 — Video Double-Lumen Tube for Secondary Pulmonary Resection · NA · not yet recruiting
- NCT07429461 — Clinical Study of SYNCAR-100 in the Treatment of Relapsed/Refractory Acute B-Lymphoblastic Leukemia · EARLY_PHASE1 · recruiting
- NCT07240766 — HRS-4642 in Combination With Nimotuzumab and Chemotherapy for BRPC With KRAS G12D Mutation · Phase 2 · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
Data sources for this page
- Trial protocol + status: ClinicalTrials.gov NCT04662294 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Zhejiang University
- Last refreshed: 4 November 2021
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04662294.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing